98%
921
2 minutes
20
Introduction: Previous studies have shown that olfactory functioning is affected by multiple sclerosis (MS). This study assessed the level of the olfactory impairment in early MS by using the Sniffin' Sticks Test.
Methods: This study included 30 patients with MS and 30 healthy controls. We collected demographic and clinical data from participants and administered the Sniffin' Sticks Test.
Results: We found no differences between the MS and control groups in odor discrimination, odor identification, and threshold discrimination identification scores, but odor threshold (OT) scores were higher in the control group than in the MS group (P=0.49). In addition, we did not find any correlation between MS patients' olfactory test scores and their scores on the Mini-Mental State Examination (MMSE), Expanded Disability Status Scale (EDSS), disease duration, history of optic neuritis, or being on immunomodulatory therapy.
Conclusion: In recent studies, odor threshold impairment seemed to be the most striking finding in patients with MS. Although the present study found a mild alteration in odor threshold, olfactory dysfunction appears to be a consequence of neurodegeneration in the higher order olfactory brain regions, which is thought to be a time-dependent process.
Download full-text PDF |
Source |
---|---|
http://www.ncbi.nlm.nih.gov/pmc/articles/PMC5012609 | PMC |
http://dx.doi.org/10.2147/NDT.S116195 | DOI Listing |
J Gerontol A Biol Sci Med Sci
September 2025
Department of Epidemiology and Biostatistics, College of Human Medicine, Michigan State University, East Lansing, MI.
Background: Poor olfaction may be associated with incident heart failure (HF) in older adults, but empirical evidence is scant.
Methods: We included 5,217 participants free of clinical HF and with a smell assessment in 2011-2013 from the Atherosclerosis Risk in Communities Study. Olfaction was measured by the 12-item Sniffin' Sticks odor identification test and defined as good (score 11-12), moderate (9-10), or poor (≤8).
Sci Rep
September 2025
Internal Medicine VI, Psychosomatic Medicine and Psychotherapy, University Hospital Tübingen, Tübingen, Germany.
Taste and smell are critical for food intake and maintaining adequate energy balance, particularly in isolated, confined, and extreme (ICE) environments. Hypoxic conditions, low humidity, and limited chemosensory exposure at Concordia Station in Antarctica may impair taste and smell functions, though research remains scarce. Gustatory and olfactory functions were assessed in 19 participants (39.
View Article and Find Full Text PDFVestn Otorinolaringol
September 2025
Medical Center ENT Plus LLC, Perm, Russia.
Unlabelled: The urgency of the problem of acute rhinosinusitis is determined by the scale of its prevalence, the tendency to prolonged course and chronization, and its active role in the formation of severe complications, which necessitates the search for new methods of diagnosis and treatment of this pathology. Assessment of the sense of smell in patients with acute rhinosinusitis is an important diagnostic criterion that allows assessing the severity of inflammation and the effectiveness of therapy.
Objective: To improve the results of treatment of acute rhinosinusitis through the use of Inflasinusans, taking into account the assessment of the clinical picture and olfactory function.
Vestn Otorinolaringol
September 2025
Federal Research Center «Krasnoyarsk Scientific Center of the Siberian Branch of the Russian Academy of Sciences» a separate division of the «Research Institute of Medical Problems of the North, Krasnoyarsk, Russia.
Relevance: Acute rhinosinusitis is one of the most common ENT diseases. Topical complex nasal spray Polydexa with phenylephrine (PE), which includes an aminoglycoside antibiotic, is effective as a local therapy. There are no data on the toxic effects of Polydexa with PE in the medical literature.
View Article and Find Full Text PDFAllergy
August 2025
Otorhinolaryngology Unit, A. Gemelli University Hospital Foundation IRCCS, Rome, Italy.
Background: Dupilumab is an effective treatment for severe, uncontrolled chronic rhinosinusitis with nasal polyps (CRSwNP). Most real-life studies have been conducted on small patient cohorts for up to 1 year.
Methods: This ambispective, multicentric, 2-year-long study evaluated dupilumab effectiveness (including treatment response, disease control, and remission) and safety in severe, uncontrolled CRSwNP patients from the DUPIREAL Italian study centers.